### 1 Integrating metabolomics and proteomics to identify novel drug targets for

## 2 heart failure and atrial fibrillation

4	Marior	n van Vugt <sup>1,2,3</sup> , Chris Finan <sup>1,2,4,5</sup> , Sandesh Chopade <sup>2,4</sup> , Rui Providencia <sup>5</sup> , Connie R.
5	Bezzir	a <sup>6</sup> , Folkert W. Asselbergs <sup>3,7,8</sup> , Jessica van Setten* <sup>1</sup> , A. Floriaan Schmidt* <sup>1,2,3,4</sup>
6	1.	Division Heart & Lungs, Department of Cardiology, University Medical Center
7		Utrecht, Utrecht University, Utrecht, The Netherlands
8	2.	Institute of Cardiovascular Science, Faculty of Population Health, University College
9		London, London, United Kingdom
10	3.	Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam
11		University Medical Centre, University of Amsterdam, Amsterdam, Netherlands
12	4.	UCL British Heart Foundation Research Accelerator, London, United Kingdom
13	5.	Health Data Research UK and Institute of Health Informatics, University College
14		London, London, United Kingdom
15	6.	Amsterdam University Medical Centers, Department of Experimental Cardiology,
16		University of Amsterdam, Amsterdam, The Netherlands
17	7.	Institute of Health Informatics, University College London, London, United Kingdom
18	8.	The National Institute for Health Research University College London Hospitals
19		Biomedical Research Centre, University College London, London, United Kingdom
20		
21	Runnii	ng title: Multi-omics in cardiac diseases
22	Word	count text: 3,356
23	Word	count abstract: 263
24	Numb	er of references: 68
25	Numb	er of tables and figures: 9

- 26 Number of (web) appendices: 3
- 27

- 1 Corresponding author:
- 2 Marion van Vugt
- 3 m.vanvugt-2@umcutrecht.nl

## 1 Abstract

3	Background. Altered metabolism plays a role in the pathophysiology of cardiac diseases,
4	such as atrial fibrillation (AF) and heart failure (HF). We aimed to identify novel plasma
5	metabolites and proteins associating with cardiac disease.
6	Methods. Mendelian randomisation (MR) was used to assess the association of 174
7	metabolites measured in up to 86,507 participants with AF, HF, dilated cardiomyopathy
8	(DCM), and non-ischemic cardiomyopathy. Subsequently, we sourced data on 1,567 plasma
9	proteins and performed cis MR to identify proteins affecting the identified metabolites as well
10	as the cardiac diseases. Proteins were prioritised on cardiac expression and druggability,
11	and mapped to biological pathways.
12	Results. We identified 35 metabolites associating with cardiac disease. AF was affected by
13	seventeen metabolites, HF by nineteen, DCM by four, and NCIM by taurine. HF was
14	particularly enriched for phosphatidylcholines (p=0.029) and DCM for acylcarnitines
15	(p=0.001). Metabolite involvement in AF was more uniform, spanning for example
16	phosphatidylcholines, amino acids, and acylcarnitines. We identified 38 druggable proteins
17	expressed in cardiac tissue, with a directionally concordant effect on metabolites and cardiac
18	disease. We recapitulated known associations, for example between the drug target of
19	digoxin (AT1B2), taurine and NICM risk. Additionally, we identified numerous novel findings,
20	such as higher RET values associating with phosphatidylcholines and decreasing AF and
21	HF, and RET is targeted by drugs such as regorafenib which has known cardiotoxic side-
22	effects. Pathway analysis implicated involvement of GDF15 signalling through RET, and
23	ghrelin regulation of energy homeostasis in cardiac pathogenesis.
24	Conclusion. This study identified 35 plasma metabolites involved with cardiac diseases and
25	linked these to 38 druggable proteins, providing actionable leads for drug development.
26	
27	Keywords: heart failure, atrial fibrillation, cardiomyopathy, metabolomics, drug

- 28 development, Mendelian randomisation, proteomics
  - 3

## 1 Introduction

2	Atrial fibrillation (AF) and heart failure (HF) are common types of cardiac disease, resulting in
3	substantial mortality and morbidity, and placing a major burden on healthcare and society <sup>1,2</sup> .
4	Despite advances in management and understanding of disease pathophysiology, AF and
5	HF prevalence remain high <sup>1,2</sup> . HF is a particularly heterogeneous disease potentially caused
6	by cardiomyopathies, such as dilated cardiomyopathy (DCM) and non-ischemic
7	cardiomyopathy (NICM).
8	
9	Aside from N-terminal prohormone of brain natriuretic peptide (NT-proBNP) used in HF,
10	troponin in ischemic cardiac disease, and D-dimers in pulmonary embolism, there are no
11	plasma measurements to inform management of cardiac disease. Analyses of diseased
12	hearts and cardiomyocytes have shown clear changes in cardiac metabolism, where
13	diseased cardiomyocytes switch to fatty acid oxidation <sup>3–5</sup> . Small sample sized and
14	predominantly cross-sectional studies of AF and HF patients have found elevated plasma
15	values of acylcarnitines (ACs), which are markers of impaired fatty acid oxidation <sup>6–12</sup> .
16	
17	Metabolic changes characterising cardiac diseases can inform drug development, which is
18	especially important for HF and AF, where currently available drugs do not necessarily
19	address underlying aetiology. For example, no novel AF drugs have been approved since
20	the 2011 introduction of the anticoagulants rivaroxaban, apixaban, and edoxaban, which are
21	indicated for stroke prevention in AF patient without addressing the underlying cause of AF.
22	
23	Both metabolites and proteins, the main targets of most drugs <sup>14</sup> , are increasingly analysed
24	by high-throughput assays measuring the plasma values of hundreds of analytes <sup>15–17</sup> .
25	Genome-wide association studies (GWAS) have now identified genetic determinants of
26	protein and metabolite values, which allow for integrative analyses identifying potential
27	associations between the protein values, metabolite values, and cardiac disease in humans.
28	Specifically, through two-sample Mendelian randomisation (MR), one can anticipate the

1	effect an exposure (e.g. a metabolite) will have on the onset of disease by sourcing genetic
2	variants strongly associated with the exposure and determining whether these variants show
3	a dose-response association with disease <sup>18,19</sup> . This approach has been extensively validated
4	for cardiovascular disease <sup>20–23</sup> , including a recent study on plasma proteins affecting cardiac
5	function and structure as well as cardiac disease <sup>24</sup> .
6	
7	In the current study we sourced data on 174 metabolites measured in up to 86,507
8	participants and performed genome-wide MR to identify metabolites associated with the
9	cardiac outcomes AF, HF, DCM, and NICM. Subsequently, we leveraged data on 1,567
10	proteins measured in up to 35,559 participants and used cis MR to identify proteins affecting
11	both the identified metabolites and the considered cardiac outcomes. We triangulated and
12	prioritised proteins with concordant effects on metabolite values and cardiac outcomes.
13	Through the integration of these omics data we identified 38 drugged and druggable proteins
14	expressed in cardiac tissue, which affected 35 metabolites and cardiac disease.
15	
15 16	Methods
15 16 17	Methods
15 16 17 18	Methods Data sources
15 16 17 18 19	Methods Data sources Genetic associations with 174 metabolites measured in up to 86,507 participants
15 16 17 18 19 20	Methods         Data sources         Genetic associations with 174 metabolites measured in up to 86,507 participants         were available from Lotta <i>et al.</i> (Supplementary Note) <sup>25</sup> . Plasma protein data were
15 16 17 18 19 20 21	Methods         Data sources         Genetic associations with 174 metabolites measured in up to 86,507 participants         were available from Lotta <i>et al.</i> (Supplementary Note) <sup>25</sup> . Plasma protein data were         available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK)
15 16 17 18 19 20 21 22	Methods <i>Data sources</i> Genetic associations with 174 metabolites measured in up to 86,507 participants were available from Lotta <i>et al.</i> (Supplementary Note) <sup>25</sup> . Plasma protein data were available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK assay, n=30,931) <sup>27</sup> , Ahola-Olli <i>et al.</i> (BioRad assay, n=8,293) <sup>28</sup> , Framingham (Luminex
15 16 17 18 19 20 21 22 23	Methods Data sources Genetic associations with 174 metabolites measured in up to 86,507 participants were available from Lotta <i>et al.</i> ( <b>Supplementary Note</b> ) <sup>25</sup> . Plasma protein data were available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK assay, n=30,931) <sup>27</sup> , Ahola-Olli <i>et al.</i> (BioRad assay, n=8,293) <sup>28</sup> , Framingham (Luminex assay, n=6,861) <sup>29</sup> , AGES-Reykjavik (SomaLogic assay, n=5,368) <sup>30</sup> , INTERVAL (SomaLogic
15 16 17 18 19 20 21 22 23 24	Methods <i>Data sources</i> Genetic associations with 174 metabolites measured in up to 86,507 participants were available from Lotta <i>et al.</i> ( <b>Supplementary Note</b> ) <sup>25</sup> . Plasma protein data were available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK assay, n=30,931) <sup>27</sup> , Ahola-Olli <i>et al.</i> (BioRad assay, n=8,293) <sup>28</sup> , Framingham (Luminex assay, n=6,861) <sup>29</sup> , AGES-Reykjavik (SomaLogic assay, n=5,368) <sup>30</sup> , INTERVAL (SomaLogic assay, n=3,301) <sup>31</sup> , Gilly <i>et al.</i> (Olink assay, n=1,328) <sup>32</sup> , and Yang <i>et al.</i> (SomaLogic assay,
15 16 17 18 19 20 21 22 23 24 25	Methods <i>Data sources</i> Genetic associations with 174 metabolites measured in up to 86,507 participants were available from Lotta <i>et al.</i> ( <b>Supplementary Note</b> ) <sup>25</sup> . Plasma protein data were available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK assay, n=30,931) <sup>27</sup> , Ahola-Olli <i>et al.</i> (BioRad assay, n=8,293) <sup>28</sup> , Framingham (Luminex assay, n=6,861) <sup>29</sup> , AGES-Reykjavik (SomaLogic assay, n=5,368) <sup>30</sup> , INTERVAL (SomaLogic assay, n=3,301) <sup>31</sup> , Gilly <i>et al.</i> (Olink assay, n=1,328) <sup>32</sup> , and Yang <i>et al.</i> (SomaLogic assay, n=636) <sup>33</sup> . Genetic associations with AF were sourced from Nielsen <i>et al.</i> (60,620 cases) <sup>34</sup> ,
15 16 17 18 19 20 21 22 23 24 25 26	Methods Data sources Genetic associations with 174 metabolites measured in up to 86,507 participants were available from Lotta <i>et al.</i> ( <b>Supplementary Note</b> ) <sup>25</sup> . Plasma protein data were available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK assay, n=30,931) <sup>27</sup> , Ahola-Olli <i>et al.</i> (BioRad assay, n=8,293) <sup>28</sup> , Framingham (Luminex assay, n=6,861) <sup>29</sup> , AGES-Reykjavik (SomaLogic assay, n=5,368) <sup>30</sup> , INTERVAL (SomaLogic assay, n=3,301) <sup>31</sup> , Gilly <i>et al.</i> (Olink assay, n=1,328) <sup>32</sup> , and Yang <i>et al.</i> (SomaLogic assay, n=636) <sup>33</sup> . Genetic associations with AF were sourced from Nielsen <i>et al.</i> (60,620 cases) <sup>34</sup> , with HF from Shah <i>et al.</i> (47,309 cases) <sup>35</sup> , with DCM from Garnier <i>et al.</i> (2,719 cases) <sup>36</sup> , and
15 16 17 18 19 20 21 22 23 24 25 26 27	Methods <i>Data sources</i> Genetic associations with 174 metabolites measured in up to 86,507 participants were available from Lotta <i>et al.</i> ( <b>Supplementary Note</b> ) <sup>25</sup> . Plasma protein data were available from eight GWAS: deCODE (SomaLogic assay, n=35,559) <sup>26</sup> , SCALLOP (OLINK assay, n=30,931) <sup>27</sup> , Ahola-Olli <i>et al.</i> (BioRad assay, n=8,293) <sup>28</sup> , Framingham (Luminex assay, n=6,861) <sup>29</sup> , AGES-Reykjavik (SomaLogic assay, n=5,368) <sup>30</sup> , INTERVAL (SomaLogic assay, n=3,301) <sup>31</sup> , Gilly <i>et al.</i> (Olink assay, n=1,328) <sup>32</sup> , and Yang <i>et al.</i> (SomaLogic assay, n=636) <sup>33</sup> . Genetic associations with AF were sourced from Nielsen <i>et al.</i> (60,620 cases) <sup>34</sup> , with HF from Shah <i>et al.</i> (47,309 cases) <sup>35</sup> , with DCM from Garnier <i>et al.</i> (2,719 cases) <sup>36</sup> , and with NICM from Aragam <i>et al.</i> (2,038 cases) <sup>37</sup> .

#### 1 Mendelian randomisation analyses

2 Genome-wide MR, considering genetic variants from across the genome, was used to 3 establish associations between metabolite values and cardiac outcomes (step 1 in Figure 4 **1A**, **Appendix Table S1-2**). Subsequently *cis* MR, sourcing genetic variants from a 200 kilobase pair window around the protein encoding gene<sup>18</sup>, was used to identify plasma 5 6 protein effects on metabolite values and cardiac outcomes (step 2-3 in Figure 1A). 7 Irrespective of the type of MR analysis, instruments were selected based on an exposure F-8 statistic of at least 24 and a minor allele frequency of at least 0.01. Additionally, variants 9 were clumped to a linkage disequilibrium r-squared of 0.3, based on a random sample of 10 5,000 unrelated UK biobank participants of European ancestry. 11 12 Analyses were conducted using the generalised least squares implementation of the

13 inverse-variance weighted (IVW) estimator, as well as with an Egger correction protecting against horizontal pleiotropy<sup>38</sup>. Influence of horizontal pleiotropy was minimised by excluding 14 15 variants with a leverage statistic larger than three times the mean, and by excluding variants with an outlier (i.e. chi-square) statistic larger than 10.83<sup>39</sup>. To ensure we had sufficient data 16 17 to accurately model the exposure effects, we discarded analyses with fewer than 6 variants. 18 Additionally, a model selection strategy was used to select the most appropriate estimator (IVW or MR-Egger)<sup>39,40</sup>, where the MR-Egger is unbiased in the presence of directional 19 20 horizontal pleiotropy. The model selection framework, originally developed by Rücker et al.<sup>41</sup>, 21 uses the difference in heterogeneity between the IVW Q-statistic and the Egger Q-statistic to 22 decide which method provides the best model to describe the available data. Furthermore, 23 due to the two-sample nature of our analyses any potential weak-instrument bias would act 24 toward a null effect, reducing power, rather than increasing type 1 errors<sup>24</sup>.

25

26 Effect estimates, multiple testing, and nomenclature

27 MR results are presented as mean difference (MD) for continuous outcomes, or odds ratios

- 28 (ORs) for binary outcomes, accompanied by 95% confidence intervals (CIs) and p-values.
  - 6

1 Metabolite effects on disease were filtered for a multiplicity corrected p-value threshold of 2 7×10<sup>-5</sup> based on the 174 available metabolites and four outcomes, which is conservative 3 considering many metabolites are correlated. Similarly, protein MR effect estimates were evaluated against a multiplicity corrected p-value of  $9 \times 10^{-7}$  for the metabolites and  $2 \times 10^{-5}$  for 4 5 the cardiac outcomes, based on the number of tested proteins (1,567 in the metabolite MR 6 and 686 in the cardiac MR) and outcomes (36 in the metabolite MR and four in the cardiac 7 MR). Proteins are referred to using their Uniprot label and presented in normal font to 8 differentiate from gene names in italic font. 9 10 Prioritisation and annotation of proteins 11 Proteins were prioritised based on the association with a plasma metabolite and a 12 directionally concordant effect on cardiac outcome. For example, if an increase in a

13 metabolite value decreased the risk of AF, a protein that increased the value of this

14 metabolite should decrease the risk of AF to be deemed concordant. In this way, robust

15 triangles of associations between the metabolites, proteins, and cardiac outcomes are

16 created (**Figure 1B**). Given that this triangulation considers evidence from three separate

17 MR analyses, with distinct underlying assumptions on horizontal pleiotropy this approach

18 identifies a robust set of results highly supported by the available data. For example, *cis* MR

19 analyses assume the absence of pre-translational pleiotropy, which may be more robust

20 compared to more distal assumptions on horizontal pleiotropy employed in genome-wide

21 MR.

22

The identified proteins were further annotated and prioritised on the presence of cardiac
mRNA expression sourcing information from the human protein atlas (HPA)<sup>42</sup>. Subsequently,
we identified genes which were overexpressed in cardiac tissue through comparisons
against the average mRNA expression across the other 60 available tissues
(Supplementary Note). Proteins are referred to as "druggable" if they are targeted by a

1	developmental drug compound, and "drugged" if they are targeted by an approved
2	compounds. For this we used data from ChEMBL v.33 and the British National Formulary
3	(BNF), which additionally provided information on indications and side-effects. Finally, the
4	Reactome <sup>43</sup> knowledgebase was queried to map all 1,567 proteins to biological pathways.
5	Pathway involvement of the prioritised proteins was compared against the full set of 1,567
6	proteins using Wald tests.
7	
8	Replicating protein associations with metabolites and cardiac disease
9	The aforementioned cis MR analyses sourced data from eight proteomic GWAS, allowing for
10	replication of the subset of identified proteins that were available in multiple studies. Of the
11	82 prioritised proteins (see results), 49 where available in multiple studies. For these 49
12	proteins the largest sample size GWAS was used for discovery and the remaining studies
13	used for replication. Replication was sought by identifying associations with the same effect
14	direction as the discovery association, and a p-value smaller than 0.05 (nominal replication)
15	and 0.05/49=0.001 (conservative replication). Please see the Supplementary Note for
16	additional details.
17	
18	Results
19	
20	Metabolite effects on cardiac outcomes
21	Genome-wide MR identified 35 metabolites associating with one or more cardiac disease
22	(Figure 2, Appendix Table S2-3). Acylcarnitines (ACs) were enriched for DCM (p=0.001;
23	Appendix Table S4), with higher values of hexadecanoylcarnitine (OR 1.51, 95%Cl 1.28;
24	1.79), octadecanoylcarnitine (OR 1.47, 95%CI 1.25; 1.73), and octadecadienoylcarnitine
25	(OR 1.38, 95%CI 1.22; 1.55) increasing DCM risk, while higher values of butyrylcarnitine
26	decreased DCM risk (OR 0.87, 95%CI 0.82; 0.93). Phosphatidylcholines (PCs) were
27	enriched for HF (p=0.029; Appendix Table S4) and all thirteen PCs associated with HF
28	elicited a risk increasing effect. We observed more uniform effects for AF, which was

1	affected by seventeen plasma metabolites. Finally, we observed that higher values of
2	plasma taurine decreased NICM risk (OR 0.48, 95%CI 0.38; 0.60; Figure 2).
3	
4	Protein effects on metabolite values and cardiac outcomes
5	We evaluated 1,567 unique plasma proteins for associations with the 35 metabolites

6 implicated in cardiac disease onset. This resulted in 686 proteins associated with one or 7 more metabolite (step 2 in Figure 1A, Appendix Figure S1). Prioritising proteins on an 8 association with cardiac outcomes identified 241 proteins (step 3 in Figure 1A, Appendix 9 Figure S2), which were pruned down to 87 proteins by identifying the proteins with a 10 directionally concordant effect on metabolites and cardiac outcomes (Table 1-4, Appendix 11 Table S5). This triangulated subset of 87 proteins included 82 that were expressed in 12 cardiac tissue, of which six (ANX11, DNJA4, NAR3, PLXA1, RF1ML, and TIG1) proteins 13 were significantly overexpressed in the heart compared to other tissues (Figure 3,

#### 14 Appendix Table S6).

15

16 ChEMBL and BNF were consulted to identify seventeen proteins that were druggable (i.e., 17 targeted by a developmental compound) and 21 that were drugged (i.e., targeted by an 18 approved compound; Figure 4, Appendix Table S7-8). Eleven of the 21 drugged proteins 19 were targeted by drugs with a cardiac indication, side-effect, or both. For example, higher 20 values of AT1B2 (targeted by HF drug digoxin) increased NICM risk and decreased plasma 21 taurine values. Furthermore, higher values of DPEP1 (associated with acetylornithine 22 values) and KPCA (associated with tetradecanoylcarnitine and PC ae C38:4 values) 23 decreased AF risk, while higher values of FA10 (associated with PC ae C42:2 and PC ae 24 C38:4 values) increased AF risk (Figure 4). DPEP1 is inhibited by cilastatin, which is 25 indicated for endocarditis and is implicated with tachycardia, KPCA is inhibited by 26 midostaurin, which is known to elicit QT-interval prolongation, and FA10 is inhibited by drugs 27 like apixaban, edoxaban, and rivaroxaban, which are commonly used to prevent stroke in 28 AF. The remaining ten drugged proteins were targeted by compounds indicated for

treatment of cancers (CAN2, EPHB1, ERAP1, GSTM3, NQO1, and PVRL4), mitochondrial
 and muscular disease (NQO1), and metabolic syndrome (CEL; Appendix Table S8-9).

3

4 Irrespective of the indication or reported side-effect, drugged or druggable proteins 5 associating with HF frequently affected phosphatidylcholines values. Higher values of ADH4 6 (targeted by nitrefazole), EDAR, EPHB1 (targeted by cancer drug vandetanib), ERAP1 7 (targeted by cancer drug tosedostat), and FCG2A decreased HF risk, while higher values of 8 APOC3, CAN2 (targeted by amyloidosis drugs bortezomib and carfilzomib), and GRAB 9 increased HF risk (Figure 4, Appendix Table S7). DCM was affected by six drugged or 10 druggable proteins, all affecting one or more acylcarnitines. Higher values of SAT2 (targeted 11 by trientine, which is in phase 2 clinical development for hypertrophic cardiomyopathy) and 12 NUDT9 decreased DCM risk, while FCG3A (the target of imgatuzumab) and CACP (targeted 13 by levocarnitine, which is being tested for AF and HF) increased DCM risk. Higher values of 14 CEL (targeted by obesity medicine orlistat), ENTP5 (targeted by the psoriasis drug 15 anthralin), GMPR2, GFRA1 (targeted by liatermin, a phase 1 compound for Parkinson's 16 disease), IBP3, and TEC (targeted by Pf-06651600, which is in clinical testing for arthritis, 17 kidney and Crohn's disease) decreased AF risk, while ENASE (targeted by AF drug 18 edoxaban), GSTM3 (targeted by carmustine), IGFR1, TDGF1 (targeted by the antibody biib-19 015 used to treat cancer), and TRYB1 (targeted by arginine, which is being tested for HF) 20 increased AF risk, affecting metabolites of various classes (Figure 4, Appendix Table S7-21 8). Four drugs target more than one prioritised protein: Cep-2563 targets KPCA and RET, 22 edoxaban targets ENASE and FA10, nitrefazole targets ADH1B and ADH4, and vandetanib 23 targets EPHB1 and RET (Appendix Table S8).

24

25 Ten pleiotropic proteins affected multiple cardiac outcomes (**Figure 5**). For example, higher

26 values of ACES (inhibited by pyridostigmine bromide, which is in phase 2 testing for HF),

27 DNJA4, and PLXB2 increased AF and HF risk, whereas higher values of IL6RA (targeted by

tocilizumab), NEC1, and RET (targeted by regorafenib, which has cardiac side-effects)

1	decreased AF and HF risk. Higher values of APOC3 and FCG3A increased the risk of HF
2	and DCM. ENOB increased the risk of HF (OR 1.05, 95%CI 1.03; 1.08), DCM (OR 1.39,
3	95%Cl 1.28; 1.50), and NICM (OR 1.24, 95%Cl 1.13; 1.35; Figure 5, Appendix Table S7).
4	
5	Identifying enriched biological pathways
6	We used the Reactome knowledgebase <sup>43</sup> to identify enriched pathways among the
7	prioritised proteins which identified three enriched pathways involving seven of the prioritised
8	proteins. Specifically, GFRA1, KPCA, and RET were involved in the "RET signalling"
9	pathway, TPSN and ERAP1 in "antigen presentation: folding, assembly and peptide loading
10	of class I MHC", and ACES and NEC1 in the "synthesis, secretion, and deacylation of
11	ghrelin" pathway ( <b>Appendix Table S10</b> ).
12	
13	Replicating protein associations with cardiac disease
14	Replication data from independent plasma protein data were available for 49 out of 82
15	prioritised proteins. Applying a nominal replication p-value of 0.05, we were able to replicate
16	the cardiac association of 38 proteins (77.6%; Appendix Table S11). The effects of 24
17	proteins were replicated more than once, with the IL6RA effects on AF and HF replicated in
18	up to five studies. Applying a multiple testing adjusted p-value cut-off, resulted in 30
19	replicated proteins (61.2%), also including IL6RA. Please see the Supplementary Note for
20	replication of the protein association with plasma metabolite values.
21	
22	Discussion
23	In the current study we integrated genetic associations with 174 metabolites and 1,567
24	proteins to identify determinants of cardiac disease relevant for de novo drug development
25	and drug repurposing. Analyses were prioritised on concordant effect direction and cardiac
26	tissue expression, identifying 82 triangulated proteins and 35 metabolites associating with
27	AF, HF, DCM, and NICM. Plasma acylcarnitine (AC) values were strongly related with DCM,
28	while phosphatidylcholine (PC) values were important determinants of HF. Metabolites

1	affecting AF spanned six metabolite classes, potentially reflecting the heterogeneous
2	aetiology of AF. We identified ten pleiotropic proteins affecting multiple cardiac traits: ACES,
3	APOC3, DNJA4, ENOB, FCG3A, IL6RA, NEC1, PLA2R, PLXB2, and RET. The 38 drugged
4	and druggable proteins included eleven proteins with a known cardiac indication, side-effect,
5	or both: ACES (donepezil), AT1B2 (digoxin), CACP (levocarnitine), DPEP1 (cilastatin),
6	ENASE (edoxaban), FA10 (apixaban), IL6RA (tocilizumab), KPCA (midostaurin), RET
7	(regorafenib), SAT2 (trientine), and TRYB1 (arginine). Pathway enrichment identified
8	proteins involved in GDF15-dependent RET signalling, ghrelin homeostasis, and MHC I
9	antigen presentation.
10	
11	ACs were strongly associated with DCM onset, with prioritised proteins affecting DCM also
12	associating with long-chain (hexadecanoylcarnitine, octadecanoylcarnitine,
13	octadecadienoylcarnitine) and short-chain (butyrylcarnitine) AC values (Table 3, Appendix
14	Table S7). Higher AC values additionally increased AF (propionylcarnitine and
15	tetradecanoylcarnitine), and HF risk (acetylcarnitine). AC values are indicators of fatty acid
16	oxidation, the main energy substrate of the healthy heart <sup>4</sup> , with particularly long-chain ACs
17	the results of fatty acid metabolism <sup>44</sup> , while short-chain ACs are more generally synthesised
18	during glucose, AA and fatty acids metabolism <sup>44</sup> . Fourteen drugged and druggable proteins
19	associated with AC plasma values (Appendix Table S7). We showed that ACES affects the
20	plasma values of several Acs and was associated with an risk increasing effect on AF and
21	HF. ACES is targeted by several drugs with cardiac side-effects and inhibited by
22	pyridostigmine bromide, which is being tested for HF (Appendix Table S8) and increases
23	heart rate variability, and reduces ventricular arrhythmias in chronic HF patients <sup>46</sup> ,
24	supporting the identified associations. NEC1 affects several PCs, AF, and HF, is a druggable
25	protein that processes hormones such as insulin and its encoding gene PCSK1 associated
26	with HF risk factors such as obesity <sup>47</sup> and abnormal glucose homeostasis <sup>48</sup> . NEC1 and
27	ACES are involved in the enriched ghrelin pathway, which regulates energy homeostasis

which plays a role in myocardial function<sup>49-52</sup>. Ghrelin was therefore proposed as a novel
 target in HF management<sup>53</sup>.

3

4 We identified thirteen PCs that increased HF risk, of which five also increased AF risk, 5 suggesting that PCs play an important role in cardiac function, which is supported by the findings that PCs are implicated in aberrant calcium handling<sup>54,55</sup>. We identified sixteen 6 7 drugged and druggable proteins affecting PC values as well as AF or HF, or both (Appendix 8 Table S7). Higher ERAP1 values (targeted by tosedostat) were shown to decrease plasma 9 PC values and HF risk, is targeted by cancer drug tosedostat, and plays a role in blood 10 pressure regulation<sup>56</sup>. Together with the not yet druggable protein TPSN, ERAP1 is involved 11 in the enriched MHC I antigen presentation pathway which is linked to CD8+ T-cell mediated 12 cardiac remodelling leading to HF. We additionally found that higher KPCA values 13 decreased AC and PC values and protected against AF. KPCA is targeted by HF drug 14 midostaurin, and is involved in the significantly enriched RET signalling pathway, together 15 with GFRA1 and RET (Appendix Table S9). The RET receptor is activated by GFRA1 and is needed for GDF15 signalling<sup>57</sup>, where GDF15 concentrations are predictive of HF 16 outcome<sup>58,59</sup>. GDF15 has also been shown to associate with stroke, bleeding, and mortality 17 18 in AF patients. Furthermore, our observation that increased RET values are protective 19 against AF and HF may indicate that the adverse effects of RET-inhibiting cancer drug 20 regoratenib, such as hypertension and myocardial infarction, are on-target (Table 1-2, 21 Figure 4-5).

22

We wish to discuss the following potential limitations. Firstly, our analyses focussed on plasma metabolites and proteins, which may not necessarily reflect concentrations in cardiac tissue <sup>61</sup>. Evidence suggests that plasma values may serve as biomarkers of intracellular energy metabolism<sup>8,62</sup> and correlate with metabolite values in cardiac tissues, for example cardiac profiles of medium- and long-chain ACs have been found to reflect plasma concentrations<sup>44</sup>. This is further supported by our observation that 82 of the 87 triangulated

1 plasma proteins were expressed in cardiac tissue. It is important to note that proteins without 2 cardiac expression can affect cardiac function, thereby contributing to disease development. 3 PCSK9, for example, was one of five proteins not expressed in cardiac tissue but is anticipated to decrease HF risk through prevention of progressive CHD<sup>21,63–65</sup>. Additionally. 4 5 animal studies suggest that PCSK9 inhibition may induce an LDL receptor-mediated improvement in cardiac lipid metabolism<sup>66</sup>, providing illustrations of plasma protein 6 7 involvement with cardiac metabolism. A second potential limitation is our reliance on high throughput assays, which differ in terms of accuracy and coverage<sup>67</sup>, and additionally 8 9 measure protein or metabolite relative values rather than concentrations. This therefore 10 implies that the reported effect estimates and their magnitudes need not directly translate to 11 anticipated clinical effects, hence small effects may nevertheless mark potentially clinically 12 impactful targets. Rather we suggest a focus on effect direction, providing information on the 13 type of perturbation (activating versus inhibiting), might be more informative. Third, while MR 14 studies are susceptible to bias through horizontal pleiotropy, we mitigate this source of bias 15 by removing potentially pleiotropic variants, employing a model selection framework, and 16 triangulating results across analysis with distinct pleiotropy assumptions. Specifically, our 17 triangulation approach minimized the potential for horizontal pleiotropy, by looking for 18 agreement across three distinct MR analyses which also made distinct assumptions on 19 horizontal pleiotropy. The robustness of this approach is highlighted by the rediscovery of 20 multiple cardiac drug targets such as edoxaban, apixaban, and rivaroxaban for AF and 21 digoxin for HF. Were the triangulation of AT1B2 with taurine and NICM is particularly 22 illustrative, because taurine supplementation may be used to replace or reduce the dosage 23 of digoxin prescription in HF<sup>68</sup>. Finally, we emphasise that we were able to replicate 24 associations for up to 77.6% of the proteins available in multiple studies. 25

In conclusion, we identify 35 metabolites and 38 drugged or druggable proteins associating
with AF, HF, DCM, and NICM. We were able to relate these findings to biological pathways

- 1 relating to energy homeostasis through ghrelin and GDF15 signalling. Our findings provide
- 2 insight into pathogenesis of cardiac disease and leads for cardiac drug development.
- 3

### 1 Data availability

- 2 All scripts and aggregated data are available online at <URL available upon publication>.
- 3

## 4 Non-standard abbreviations and acronyms

- 5 AA = amino acid
- 6 AC = acylcarnitine
- 7 AF = atrial fibrillation
- 8 BNF = British National Formulary
- 9 CI = confidence interval
- 10 DCM = dilated cardiomyopathy
- 11 EGFR = epidermal growth factor receptor
- 12 GWAS = genome-wide association studies
- 13 HF = heart failure
- 14 HPA = human protein atlas
- 15 IQR = interquartile range
- 16 IVW = inverse-variance weighted
- 17 LPC = lysophosphatidylcholine
- 18 MD = mean difference
- 19 MR = mendelian randomisation
- 20 NICM = non-ischemic cardiomyopathy
- 21 nTPM = normalised transcripts per million
- 22 NT-proBNP = N-terminal prohormone of brain natriuretic peptide
- 23 OR = odds ratio
- 24 PC = phosphatidylcholine
- 25 SM = sphingomyelin

#### 1 References

- 2 1. Elliott, A. D., Middeldorp, M. E., Van Gelder, I. C., Albert, C. M. & Sanders, P.
- 3 Epidemiology and modifiable risk factors for atrial fibrillation. Nat. Rev. Cardiol. 1–14

4 (2023).

- 5 2. Ziaeian, B. & Fonarow, G. C. Epidemiology and aetiology of heart failure. *Nat. Rev.*
- 6 *Cardiol.* **13**, 368–378 (2016).
- Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R. & Abel, E. D. Cardiac energy
   metabolism in heart failure. *Circ. Res.* **128**, 1487–1513 (2021).
- 9 4. Dambrova, M. et al. Acylcarnitines: nomenclature, biomarkers, therapeutic potential,
- 10 drug targets, and clinical trials. *Pharmacol. Rev.* **74**, 506–551 (2022).
- 11 5. Wiersma, M. et al. Mitochondrial dysfunction underlies cardiomyocyte remodeling in
- 12 experimental and clinical atrial fibrillation. *Cells* **8**, 1202 (2019).
- 13 6. Ueland, T. et al. Disturbed carnitine regulation in chronic heart failure—increased plasma
- 14 levels of palmitoyl-carnitine are associated with poor prognosis. *Int. J. Cardiol.* **167**,
- 15 1892–1899 (2013).
- 16 7. Ahmad, T. et al. Prognostic implications of long-chain acylcarnitines in heart failure and
- 17 reversibility with mechanical circulatory support. J. Am. Coll. Cardiol. 67, 291–299
- 18 (2016).
- 19 8. Hunter, W. G. et al. Metabolomic profiling identifies novel circulating biomarkers of
- 20 mitochondrial dysfunction differentially elevated in heart failure with preserved versus
- reduced ejection fraction: evidence for shared metabolic impairments in clinical heart
  failure. *J. Am. Heart Assoc.* 5, e003190 (2016).
- 23 9. Ruiz, M. et al. Circulating acylcarnitine profile in human heart failure: a surrogate of fatty
- 24 acid metabolic dysregulation in mitochondria and beyond. *Am. J. Physiol.-Heart Circ.*
- 25 *Physiol.* **313**, H768–H781 (2017).
- 26 10. Zordoky, B. N. *et al.* Metabolomic fingerprint of heart failure with preserved ejection
  27 fraction. *PloS One* **10**, e0124844 (2015).

1	11.	Ruiz-Canela, M. et al. Plasma acylcarnitines and risk of incident heart failure and atrial
2		fibrillation: the Prevención con dieta mediterránea study. Rev. Esp. Cardiol. Engl. Ed. 75,
3		649–658 (2022).
4	12.	Smith, E., Fernandez, C., Melander, O. & Ottosson, F. Altered acylcarnitine metabolism
5		is associated with an increased risk of atrial fibrillation. J. Am. Heart Assoc. 9, e016737
6		(2020).
7	13.	Carubelli, V. et al. Amino acids and derivatives, a new treatment of chronic heart failure?
8		<i>Heart Fail. Rev.</i> <b>20</b> , 39–51 (2015).
9	14.	Finan, C. et al. The druggable genome and support for target identification and validation
10		in drug development. Sci. Transl. Med. 9, eaag1166 (2017).
11	15.	Soininen, P. et al. High-throughput serum NMR metabonomics for cost-effective holistic
12		studies on systemic metabolism. Analyst 134, 1781–1785 (2009).
13	16.	Würtz, P. et al. Quantitative serum nuclear magnetic resonance metabolomics in large-
14		scale epidemiology: a primer on-omic technologies. Am. J. Epidemiol. 186, 1084–1096
15		(2017).
16	17.	Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery.
17		Nat. Preced. 1–1 (2010).
18	18.	Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. Nat.
19		<i>Commun.</i> <b>11</b> , 3255 (2020).
20	19.	Schmidt, A. F., Hingorani, A. D. & Finan, C. Human genomics and drug development.
21		Cold Spring Harb. Perspect. Med. 12, (2022).
22	20.	Consortium, I6 R. M. R. A. (IL6R M. & others. The interleukin-6 receptor as a target for
23		prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet
24		<b>379</b> , 1214–1224 (2012).
25	21.	Schmidt, A. F. et al. Cholesteryl ester transfer protein (CETP) as a drug target for
26		cardiovascular disease. Nat. Commun. 12, 5640 (2021).
27	22.	Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the
28		plasma proteome on complex diseases. Nat. Genet. 52, 1122–1131 (2020).
	18	

1 23. Cupido, A. J. et al. Joint genetic inhibition of PCSK9 and CETP and the association v	with
---	------

- 2 coronary artery disease: a factorial Mendelian randomization study. JAMA Cardiol. 7,
- 3 955-964 (2022).
- 4 24. Schmidt, A. F. et al. Druggable proteins influencing cardiac structure and function:
- 5 Implications for heart failure therapies and cancer cardiotoxicity. Sci. Adv. 9, eadd4984
- 6 (2023).
- 7 25. Lotta, L. A. et al. A cross-platform approach identifies genetic regulators of human
- 8 metabolism and health. Nat. Genet. 53, 54-64 (2021).
- 9 26. Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and
- 10 disease. Nat. Genet. 53, 1712-1721 (2021).
- 11 27. Folkersen, L. et al. Genomic and drug target evaluation of 90 cardiovascular proteins in
- 12 30,931 individuals. Nat. Metab. 2, 1135-1148 (2020).
- 13 28. Ahola-Olli, A. V. et al. Genome-wide association study identifies 27 loci influencing
- 14 concentrations of circulating cytokines and growth factors. Am. J. Hum. Genet. 100, 40-15 50 (2017).
- 16 29. Yao, C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal
- 17 genes and pathways for cardiovascular disease. Nat. Commun. 9, 3268 (2018).
- 18 30. Gudjonsson, A. et al. A genome-wide association study of serum proteins reveals shared
- 19 loci with common diseases. Nat. Commun. 13, 480 (2022).
- 20 31. Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 21
- (2018).
- 22 32. Gilly, A. et al. Whole-genome sequencing analysis of the cardiometabolic proteome. Nat.
- 23 Commun. 11, 6336 (2020).
- 24 33. Yang, C. et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes
- 25 proteins implicated in neurological disorders. Nat. Neurosci. 24, 1302-1312 (2021).
- 26 34. Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into atrial
- 27 fibrillation biology. Nat. Genet. 50, 1234–1239 (2018).

1	35. Shah, S. et al. Genome-wide association and Mendelian randomisation analysis provide
2	insights into the pathogenesis of heart failure. Nat. Commun. 11, 1-12 (2020).
3	36. Garnier, S. et al. Genome-wide association analysis in dilated cardiomyopathy reveals
4	two new players in systolic heart failure on chromosomes 3p25. 1 and 22q11. 23. Eur.
5	<i>Heart J.</i> <b>42</b> , 2000–2011 (2021).
6	37. Aragam, K. G. et al. Phenotypic refinement of heart failure in a national biobank
7	facilitates genetic discovery. Circulation 139, 489–501 (2019).
8	38. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
9	instruments: effect estimation and bias detection through Egger regression. Int. J.
10	<i>Epidemiol.</i> <b>44</b> , 512–525 (2015).
11	39. Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary
12	data Mendelian randomization. Stat. Med. 36, 1783–1802 (2017).
13	40. Bowden, J. et al. Improving the visualization, interpretation and analysis of two-sample
14	summary data Mendelian randomization via the Radial plot and Radial regression. Int. J.
15	<i>Epidemiol.</i> <b>47</b> , 1264–1278 (2018).
16	41. Rücker, G., Schwarzer, G., Carpenter, J. R., Binder, H. & Schumacher, M. Treatment-
17	effect estimates adjusted for small-study effects via a limit meta-analysis. Biostatistics
18	<b>12</b> , 122–142 (2011).
19	42. Uhlen, M. et al. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 28,
20	1248–1250 (2010).
21	43. Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498-
22	D503 (2020).
23	44. Makrecka-Kuka, M. et al. Plasma acylcarnitine concentrations reflect the acylcarnitine
24	profile in cardiac tissues. Sci. Rep. 7, 17528 (2017).
25	45. Rasooly, D. et al. Genome-wide association analysis and Mendelian randomization
26	proteomics identify drug targets for heart failure. Nat. Commun. 14, 3826 (2023).

1	46. Behling, A. et al. Cholinergic stimulation with pyridostigmine reduces ventricular
2	arrhythmia and enhances heart rate variability in heart failure. Am. Heart J. 146, 494–
3	500 (2003).
4	47. Benzinou, M. et al. Common nonsynonymous variants in PCSK1 confer risk of obesity.
5	Nat. Genet. 40, 943–945 (2008).
6	48. Heni, M. et al. Association of obesity risk SNPs in PCSK1 with insulin sensitivity and
7	proinsulin conversion. (2010).
8	49. Nagaya, N. et al. Effects of ghrelin administration on left ventricular function, exercise
9	capacity, and muscle wasting in patients with chronic heart failure. Circulation 110,
10	3674–3679 (2004).
11	50. Beiras-Fernandez, A. et al. Altered myocardial expression of ghrelin and its receptor
12	(GHSR-1a) in patients with severe heart failure. Peptides 31, 2222–2228 (2010).
13	51. Ma, T. et al. Ghrelin expression and significance in 92 patients with atrial fibrillation.
14	Anatol. J. Cardiol. 18, 99 (2017).
15	52. Yuan, MJ., Li, W. & Zhong, P. Research progress of ghrelin on cardiovascular disease.
16	<i>Biosci. Rep.</i> <b>41</b> , BSR20203387 (2021).
17	53. Nagaya, N. & Kangawa, K. Therapeutic potential of ghrelin in the treatment of heart
18	failure. <i>Drugs</i> <b>66</b> , 439–448 (2006).
19	54. Li, Y. et al. Enrichment of endoplasmic reticulum with cholesterol inhibits sarcoplasmic-
20	endoplasmic reticulum calcium ATPase-2b activity in parallel with increased order of
21	membrane lipids: implications for depletion of endoplasmic reticulum calcium stores and
22	apoptosis in cholesterol-loaded macrophages. J. Biol. Chem. 279, 37030-37039 (2004).
23	55. Fu, S. et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver
24	endoplasmic reticulum stress in obesity. Nature 473, 528–531 (2011).
25	56. Cifaldi, L., Romania, P., Lorenzi, S., Locatelli, F. & Fruci, D. Role of endoplasmic
26	reticulum aminopeptidases in health and disease: from infection to cancer. Int. J. Mol.
27	<i>Sci.</i> <b>13</b> , 8338–8352 (2012).

1	57.	Buchholz, K. et al. Expression of the Body-Weight Signaling Players: GDF15, GFRAL
2		and RET and their clinical relevance in Gastric Cancer. J. Cancer 12, 4698 (2021).
3	58.	Rochette, L., Zeller, M., Cottin, Y. & Vergely, C. Insights into mechanisms of GDF15 and
4		receptor GFRAL: therapeutic targets. Trends Endocrinol. Metab. 31, 939–951 (2020).
5	59.	Xu, J. et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released
6		from the myocardium in association with SMAD protein activation. Circ. Res. 98, 342-
7		350 (2006).
8	60.	Bouchot, O. et al. Low circulating levels of growth differentiation factor-15 before
9		coronary artery bypass surgery may predict postoperative atrial fibrillation. J.
10		Cardiothorac. Vasc. Anesth. 29, 1131–1139 (2015).
11	61.	Flam, E. et al. Integrated landscape of cardiac metabolism in end-stage human
12		nonischemic dilated cardiomyopathy. Nat. Cardiovasc. Res. 1, 817–829 (2022).
13	62.	Rinaldo, P., Cowan, T. M. & Matern, D. Acylcarnitine profile analysis. Genet. Med. 10,
14		151–156 (2008).
15	63.	Cohen, J. C., Boerwinkle, E., Mosley Jr, T. H. & Hobbs, H. H. Sequence variations in
16		PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354,
17		1264–1272 (2006).
18	64.	Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular
19		disease. N. Engl. J. Med. <b>376</b> , 1713–1722 (2017).
20	65.	Schmidt, A. F. et al. PCSK9 monoclonal antibodies for the primary and secondary
21		prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2017).
22	66.	Da Dalt, L. et al. PCSK9 deficiency rewires heart metabolism and drives heart failure
23		with preserved ejection fraction. Eur. Heart J. 42, 3078–3090 (2021).
24	67.	Katz, D. H. et al. Proteomic profiling platforms head to head: leveraging genetics and
25		clinical traits to compare aptamer-and antibody-based methods. Sci. Adv. 8, eabm5164
26		(2022).
27	68.	Schaffer, S. & Kim, H. W. Effects and mechanisms of taurine as a therapeutic agent.
28		<i>Biomol. Ther.</i> <b>26</b> , 225 (2018).

## Tables

## Table 1. Overview and characteristics of prioritised proteins and metabolites associated with AF

Uniprot ID	Protein	Druggability*	Metabolite class(es)*	No. metabolites*	Metabolite effect*	Cardiac effect*	No. drugs*	Cardiac drug effect*
P22303	ACES	Drugged	Acylcarnitines	1	Increasing	1.09 (1.05; 1.13)	23	Yes
P14621	ACYP2	Not yet druggable	Amino acids	1	Increasing	0.84 (0.80; 0.88)	0	
075882	ATRN	Not yet druggable	Acylcarnitines	1	Increasing	0.94 (0.93; 0.96)	0	
075973	C1QRF	Not yet druggable	Sphingomyelins, Phosphatidylcholines	2	Increasing	1.05 (1.04; 1.07)	0	
P80075	CCL8	Not yet druggable	Lysophosphatidylcholines	1	Increasing	1.02 (1.01; 1.03)	0	
P19835	CEL	Drugged	Biogenic amines	1	Decreasing	0.95 (0.93; 0.97)	1	
Q8WW22	DNJA4	Not yet druggable	Phosphatidylcholines	1	Decreasing	1.34 (1.26; 1.44)	0	
P16444	DPEP1	Drugged	Biogenic amines	1	Decreasing	0.97 (0.96; 0.98)	2	Yes
Q8NFI3	ENASE	Drugged	Lysophosphatidylcholines	1	Decreasing	1.06 (1.03; 1.08)	12	Yes
075356	ENTP5	Drugged	Acylcarnitines	1	Increasing	0.89 (0.86; 0.93)	1	
P00742	FA10	Drugged	Phosphatidylcholines	2	Increasing	1.11 (1.06; 1.15)	13	Yes
P16930	FAAA	Not yet druggable	Phosphatidylcholines	1	Decreasing	0.90 (0.88; 0.92)	0	
Q6BAA4	FCRLB	Not yet druggable	Amino acids	1	Increasing	1.13 (1.08; 1.18)	0	
095479	G6PE	Not yet druggable	Phosphatidylcholines	1	Decreasing	0.96 (0.94; 0.98)	0	
P56159	GFRA1	Druggable	Phosphatidylcholines	1	Increasing	0.91 (0.89; 0.94)	1	
094923	GLCE	Not yet druggable	Sphingomyelins, Phosphatidylcholines	2	Mixed	0.94 (0.93; 0.95)	0	
Q9P2T1	GMPR2	Druggable	Phosphatidylcholines	2	Increasing	0.93 (0.90: 0.96)	0	
Q9UJJ9	GNPTG	Not vet druggable	Sphingomyelins	1	Increasing	0.94 (0.92: 0.96)	0	
P21266	GSTM3	Drugged	Sphingomyelins. Biogenic amines	2	Mixed	1.04 (1.02; 1.05)	1	
P17936	IBP3	Druggable	Acvicarnitines	1	Increasing	0.93 (0.91: 0.96)	0	
Q9H665	IGFR1	Druggable	Biogenic amines	1	Decreasing	1.05 (1.03; 1.08)	0	
Q13478	IL18R	Druggable	Acylcarnitines, Lysophosphatidylcholines	2	Increasing	0.95 (0.94: 0.97)	1	
P08887	IL6RA	Drugged	Sphingomyelins	1	Increasing	0.96 (0.96; 0.97)	7	Yes
P20155	ISK2	Not vet druggable	Phosphatidylcholines	1	Increasing	1.10 (1.07: 1.14)	0	
P17252	KPCA	Drugged	Acylcarnitines Phosphatidylcholines	2	Increasing	$0.81(0.74 \cdot 0.89)$	5	Yes
075023	LIRB5	Not vet druggable	Amino acids	1	Increasing	1.02 (1.01: 1.03)	0	
015232	MATN3	Not vet druggable	Sphingomyelins, Phosphatidylcholines	2	Increasing	0.97 (0.96; 0.98)	Ő	
P61244	MAX	Druggable	Lysophosphatidylcholines	1	Decreasing	1.09 (1.05: 1.14)	0	
029983	MICA	Not vet druggable	Acylcarnitines Amino acids	2	Increasing	1.02 (1.02, 1.03)	0	
Q13508	NAR3	Not vet druggable	Amino acids I vsophosphatidylcholines	2	Increasing	1.07 (1.04: 1.11)	0	
P29120	NFC1	Druggable	Phosphatidylcholines Sphingomyelins	3	Increasing	0.96 (0.94: 0.97)	0	
Q14554	PDIA5	Not vet druggable	Amino acids Phosphatidylcholines Biogenic amines	3	Mixed	1.03 (1.02: 1.05)	0	
015031	PLXB2	Not vet druggable	Amino acids, Phosphatidylcholines, Diegenie aminee	2	Increasing	1.05 (1.02; 1.06)	0	
Q6UW15	REG3G	Not vet druggable	Phosphatidylcholines	1	Increasing	0.97 (0.96: 0.98)	0	
P07949	RET	Drugged	Acylearnitines Amino acids	2	Increasing	0.94 (0.93: 0.95)	14	Yes
P13385	TDGF1	Druggou	Sphingomyelins Phosphatidylcholines	2	Mixed	1 03 (1 02: 1 04)	1	100
P42680	TEC	Druggable	Sphingomyelins	1	Increasing	0.87 (0.83: 0.90)	1	
092563	TICN2	Not vet drugged	Acylearnitines Phosphatidyleholines	2	Increasing	0.91 (0.89: 0.94)	0	
P35625	TIMP3	Not vet druggable	Phosphatidylcholines	1	Decreasing	1 03 (1 02: 1 04)	0	
015533	TPSN	Not vet druggable	Phosphatidylcholines	4	Increasing	0.96 (0.95: 0.98)	0	
015661	TRVB1	Drugged		1	Increasing	1.02 (1.01: 1.03)	1	Ves
D/07/6	TSD3	Not vet druggable	Phoenhatidulcholines	2	Increasing	0.55 (0.44: 0.69)	0	103
F49140	1050	Not yet utuggable	i nospitatu ylutionines	4	increasing	0.00 (0.44, 0.09)	U	

N.B. *Druggability* – whether the protein is targeted by a developmental ("druggable") or approved ("drugged") compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of some and decrease values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

Uniprot ID	Protein	Druggability*	Metabolite class(es)*	No. metabolites*	Metabolite effect*	Cardiac effect*	No. drugs*	Cardiac drug effect*
P22303	ACES	Drugged	Acylcarnitines	1	Increasing	1.06 (1.04; 1.08)	23	Yes
P00326	ADH1B	Druggable	Acylcarnitines	1	Increasing	1.14 (1.08; 1.20)	2	
P08319	ADH4	Druggable	Phosphatidylcholines	5	Increasing	0.70 (0.61; 0.80)	1	
P50995	ANX11	Not yet druggable	Amino acids	1	Increasing	0.86 (0.82; 0.90)	0	
P02656	APOC3	Druggable	Phosphatidylcholines, Acylcarnitines	5	Increasing	1.29 (1.18; 1.41)	0	
P17655	CAN2	Drugged	Amino acids, Phosphatidylcholines	2	Increasing	1.21 (1.13; 1.29)	2	
Q9UBX1	CATF	Drugged	Amino acids	1	Increasing	0.92 (0.90; 0.94)	2	
Q96EE4	CC126	Not yet druggable	Amino acids	1	Increasing	1.07 (1.04; 1.09)	0	
Q5QGZ9	CL12A	Not yet druggable	Amino acids	1	Increasing	0.99 (0.98; 0.99)	0	
Q8WW22	DNJA4	Not yet druggable	Amino acids	1	Increasing	1.23 (1.14; 1.33)	0	
Q9UNE0	EDAR	Druggable	Phosphatidylcholines	6	Increasing	0.92 (0.88; 0.95)	0	
P13929	ENOB	Not yet druggable	Amino acids, Phosphatidylcholines	2	Increasing	1.05 (1.03; 1.08)	0	
P54762	EPHB1	Drugged	Phosphatidylcholines, Amino acids	2	Mixed	0.95 (0.93; 0.97)	1	
Q9NZ08	ERAP1	Druggable	Phosphatidylcholines	2	Increasing	0.97 (0.96; 0.98)	1	
P12318	FCG2A	Druggable	Phosphatidylcholines	1	Increasing	0.99 (0.98; 0.99)	0	
P08637	FCG3A	Druggable	Phosphatidylcholines	1	Increasing	1.01 (1.01; 1.02)	1	
P10144	GRAB	Drugged	Phosphatidylcholines	2	Increasing	1.21 (1.11; 1.32)	0	
Q96D42	HAVR1	Not yet druggable	Amino acids	1	Increasing	1.06 (1.04; 1.08)	0	
P08887	IL6RA	Drugged	Sphingomyelins	1	Increasing	0.98 (0.97; 0.99)	7	Yes
Q07866	KLC1	Not yet druggable	Amino acids, Sphingomyelins	2	Increasing	1.28 (1.20; 1.38)	0	
Q29980	MICB	Not yet druggable	Phosphatidylcholines	3	Increasing	1.05 (1.04; 1.07)	0	
Q9UNW1	MINP1	Not yet druggable	Phosphatidylcholines	1	Increasing	0.80 (0.73; 0.88)	0	
014931	NCTR3	Not yet druggable	Phosphatidylcholines	1	Increasing	1.03 (1.02; 1.05)	0	
P29120	NEC1	Druggable	Phosphatidylcholines	3	Increasing	0.97 (0.96; 0.99)	0	
P15559	NQO1	Drugged	Sphingomyelins	1	Increasing	0.97 (0.96; 0.98)	4	
Q13018	PLA2R	Druggable	Amino acids	2	Increasing	1.01 (1.01; 1.02)	0	
Q9UIW2	PLXA1	Not yet druggable	Sphingomyelins	1	Increasing	0.90 (0.87; 0.92)	0	
O 15031	PLXB2	Not yet druggable	Phosphatidylcholines	2	Increasing	1.03 (1.02; 1.04)	0	
P07949	RET	Drugged	Acylcarnitines, Phosphatidylcholines	5	Increasing	0.97 (0.96; 0.98)	14	Yes
Q96DX8	RTP4	Not yet druggable	Amino acids	1	Increasing	1.08 (1.06; 1.11)	0	
Q9UH65	SWP70	Not yet druggable	Phosphatidylcholines	3	Increasing	0.96 (0.94; 0.97)	0	
P22105	TENX	Not yet druggable	Amino acids	1	Increasing	1.03 (1.02; 1.04)	0	
P49788	TIG1	Not yet druggable	Phosphatidylcholines, Sphingomyelins	3	Increasing	1.03 (1.02; 1.03)	0	
P25311	ZA2G	Not yet druggable	Phosphatidylcholines	2	Increasing	0.92 (0.90; 0.95)	0	

Table 2. Overview and characteristics of prioritised proteins and metabolites associated with HF

N.B. *Druggability* – whether the protein is targeted by a developmental ("druggable") or approved ("drugged") compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the

protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

Uniprot ID	Protein	Druggability*	Metabolite class(es)*	No. metabolites*	Metabolite effect*	Cardiac effect*	No. drugs*	Cardiac drug effect*
P02654	APOC1	Not yet druggable	Acylcarnitines	1	Increasing	1.49 (1.26; 1.77)	0	
P02656	APOC3	Druggable	Acylcarnitines	2	Increasing	2.15 (1.62; 2.85)	0	
P43155	CACP	Drugged	Acylcarnitines	1	Decreasing	3.15 (2.03; 4.90)	1	Yes
Q9NZK5	CECR1	Not yet druggable	Acylcarnitines	1	Decreasing	0.82 (0.76; 0.90)	0	
P09543	CN37	Not yet druggable	Acylcarnitines	2	Increasing	0.50 (0.43; 0.57)	0	
P13929	ENOB	Not yet druggable	Acylcarnitines	1	Decreasing	1.39 (1.28; 1.50)	0	
P08637	FCG3A	Druggable	Acylcarnitines	1	Decreasing	1.07 (1.05; 1.10)	1	
Q4G148	GXLT1	Not yet druggable	Acylcarnitines	1	Increasing	1.68 (1.34; 2.10)	0	
Q8NFM7	l17RD	Not yet druggable	Acylcarnitines	1	Increasing	0.76 (0.68; 0.86)	0	
Q9BXS1	IDI2	Not yet druggable	Acylcarnitines	1	Increasing	1.94 (1.57; 2.41)	0	
Q9BW91	NUDT9	Druggable	Acylcarnitines	1	Increasing	0.27 (0.15; 0.49)	0	
Q13018	PLA2R	Druggable	Acylcarnitines	1	Increasing	0.92 (0.91; 0.94)	0	
Q9UGC7	RF1ML	Not yet druggable	Acylcarnitines	1	Increasing	2.35 (1.93; 2.86)	0	
Q96F10	SAT2	Drugged	Acylcarnitines	3	Mixed	0.73 (0.64; 0.84)	1	Yes

Table 3. Overview and characteristics of prioritised proteins and metabolites associated with DCM

N.B. *Druggability* – whether the protein is targeted by a developmental ("druggable") or approved ("drugged") compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

Uniprot ID	Protein	Druggability*	Metabolite class(es)*	No. metabolites*	Metabolite effect*	Cardiac effect*	No. drugs*	Cardiac drug effect*
P13929	ENOB	Not yet druggable	Biogenic amines	1	Decreasing	1.24 (1.13; 1.35)	0	
P14415	AT1B2	Drugged	Biogenic amines	1	Decreasing	1.33 (1.19; 1.49)	6	Yes
Q96NY8	PVRL4	Drugged	Biogenic amines	1	Decreasing	0.32 (0.20; 0.51)	1	

N.B. *Druggability* – whether the protein is targeted by a developmental ("druggable") or approved ("drugged") compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

#### Figures

#### Figure 1. Study to identify plasma proteins and metabolites affecting cardiac disease

A) Flowchart of the analysis steps; B) A triangulation diagram, illustrating how a robust set of directionally concordant proteins was identified affecting plasma metabolite levels as well as cardiac disease. The red plus indicates a risk-increasing effect, while the blue minus indicates a risk-decreasing effect; C) Annotated network of prioritised metabolites, proteins, and outcomes for which the metabolites have at least 20% associated common proteins and belong to the metabolite class acylcarnitine. Prioritised directionally concordant proteins are represented by circles, metabolites by diamonds, outcomes by triangles. Circle colours represent protein druggability. Increasing effects are displayed by a red arrow, decreasing effects by a blue arrow. See **Supplementary Note** for more details.

Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HF = heart failure, MR = mendelian randomisation, NICM = non-ischemic cardiomyopathy.

#### Figure 2. Plasma metabolites associating with at least one cardiac outcome

N.B. For visualisation purposes, the p-values were truncated to a -log(10) of 10. Multiplicity corrected significant associations are depicted by a star, non-significant associations by a dot. The top row indicates the number of druggable proteins reflecting information retrieved from BNF and ChEMBL. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al.* (60,620 AF cases)<sup>34</sup>, Shah *et al.* (47,309 HF cases)<sup>35</sup>, Garnier *et al.* (2,719 DCM cases)<sup>36</sup>, and Aragam *et al.* (2,038 NICM cases)<sup>37</sup>. See the Methods section additional details, and Supplementary Table S2 for the underlying numerical data. Abbreviations: a = acyl residue, aa = diacyl residue, ae = acyl-alkyl residue, AF = atrial fibrillation, DCM = dilated cardiomyopathy, HF = heart failure, LPC = lysophosphatidylcholine, NICM = non-ischemic cardiomyopathy, PC = phosphatidylcholine, SM = sphingomyelin.

## Figure 3. Cardiac mRNA expression of the subset of directionally concordant proteins

#### affecting cardiac disease

N.B. Proteins are referred to using their Uniprot label and proteins in bold font are overexpressed in cardiac tissue relative to non-cardiac tissue. Data were sourced from the human protein atlas; see Methods section.

# Figure 4. Forest plots of cardiac outcome effect of prioritised drugged or druggable proteins

N.B. Metabolite class of the metabolites affected by the protein are indicated on the right yaxis. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al.*  $(60,620 \text{ AF cases})^{34}$ , Shah *et al.*  $(47,309 \text{ HF cases})^{35}$ , Garnier *et al.*  $(2,719 \text{ DCM cases})^{36}$ , and Aragam *et al.*  $(2,038 \text{ NICM cases})^{37}$ . See the Methods section for a more detailed description and **Appendix Table S7-8** for the full numerical results. Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HF = heart failure, NICM = non-ischemic cardiomyopathy, OR = odds ratio.

# Figure 5. Forest plot of prioritised proteins associating with more than one cardiac outcome

N.B. . Metabolite class of the metabolites affected by the protein are indicated on the right yaxis. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al.*  $(60,620 \text{ AF cases})^{34}$ , Shah *et al.*  $(47,309 \text{ HF cases})^{35}$ , Garnier *et al.*  $(2,719 \text{ DCM cases})^{36}$ , and Aragam *et al.*  $(2,038 \text{ NICM cases})^{37}$ . See the Methods section for a more detailed description and **Appendix Table S7** for the full numerical results. Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HF = heart failure, NICM = non-ischemic cardiomyopathy, OR = odds ratio.





в

Effect direction

---> Decreasing

---- Increasing

Protein druggability

Druggable

Drugged

Not yet druggable









